Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial

RCT (n=90) found addition of gemcitabine to pazopanib therapy improved progression free survival at 12 weeks (74% for combination therapy vs 47% for pazopanib alone, HR 1.6, 90%CI 1.15-2.23). However the overall survival rate was similar (13.1 vs 11.2 months, p=0.83).

JAMA Oncology